Russell Booth Hall
Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Respiration, Artificial | 16 | 2014 | 330 | 3.430 |
Why?
| Pemphigus | 6 | 2021 | 16 | 3.340 |
Why?
| Intensive Care Units | 16 | 2014 | 374 | 3.160 |
Why?
| Critical Illness | 14 | 2014 | 285 | 3.050 |
Why?
| Muscle Weakness | 6 | 2014 | 71 | 2.300 |
Why?
| Critical Care | 12 | 2014 | 370 | 1.970 |
Why?
| Polyneuropathies | 4 | 2014 | 25 | 1.830 |
Why?
| Immunoglobulin G | 4 | 2021 | 483 | 1.570 |
Why?
| Conscious Sedation | 7 | 2014 | 73 | 1.160 |
Why?
| Autoantibodies | 4 | 2021 | 261 | 1.120 |
Why?
| Muscle Relaxants, Central | 2 | 2013 | 12 | 1.070 |
Why?
| Neuromuscular Blockade | 2 | 2013 | 37 | 1.040 |
Why?
| Length of Stay | 7 | 2014 | 703 | 1.010 |
Why?
| Desmoglein 3 | 2 | 2020 | 7 | 1.000 |
Why?
| Desmoglein 1 | 2 | 2020 | 8 | 1.000 |
Why?
| Hypnotics and Sedatives | 5 | 2014 | 133 | 0.950 |
Why?
| Receptors, Fc | 2 | 2021 | 34 | 0.910 |
Why?
| Patient Transfer | 3 | 2012 | 94 | 0.880 |
Why?
| Receptor, Muscarinic M3 | 1 | 2020 | 13 | 0.860 |
Why?
| Prednisone | 3 | 2020 | 264 | 0.790 |
Why?
| Receptors, Nicotinic | 1 | 2020 | 131 | 0.780 |
Why?
| Thoracic Diseases | 2 | 2014 | 26 | 0.640 |
Why?
| Humans | 64 | 2021 | 84146 | 0.600 |
Why?
| Skin | 5 | 2020 | 561 | 0.570 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 947 | 0.570 |
Why?
| Benzodiazepines | 2 | 2012 | 62 | 0.560 |
Why?
| Dermatologic Agents | 1 | 2015 | 69 | 0.540 |
Why?
| Interactive Ventilatory Support | 1 | 2013 | 5 | 0.540 |
Why?
| Hospital Mortality | 4 | 2015 | 333 | 0.540 |
Why?
| Pulmonary Medicine | 1 | 2014 | 49 | 0.530 |
Why?
| Delirium | 3 | 2014 | 67 | 0.530 |
Why?
| Respiratory Rate | 1 | 2013 | 18 | 0.530 |
Why?
| Inpatients | 2 | 2016 | 277 | 0.530 |
Why?
| Ventilator-Induced Lung Injury | 1 | 2013 | 30 | 0.530 |
Why?
| Deep Sedation | 1 | 2013 | 15 | 0.520 |
Why?
| Life Support Care | 2 | 2012 | 48 | 0.520 |
Why?
| Analgesia | 1 | 2013 | 57 | 0.500 |
Why?
| Hospitals, Chronic Disease | 1 | 2012 | 2 | 0.480 |
Why?
| Intermediate Care Facilities | 1 | 2011 | 2 | 0.470 |
Why?
| Middle Aged | 35 | 2021 | 25699 | 0.460 |
Why?
| Health Services Research | 2 | 2012 | 139 | 0.450 |
Why?
| Skilled Nursing Facilities | 1 | 2011 | 33 | 0.450 |
Why?
| Aged | 31 | 2021 | 18604 | 0.440 |
Why?
| Physical Therapy Modalities | 4 | 2014 | 76 | 0.430 |
Why?
| Shock, Septic | 2 | 2013 | 100 | 0.430 |
Why?
| Analgesics, Opioid | 2 | 2012 | 381 | 0.420 |
Why?
| Male | 39 | 2021 | 42131 | 0.410 |
Why?
| Biomedical Research | 2 | 2012 | 357 | 0.410 |
Why?
| Female | 38 | 2021 | 45020 | 0.410 |
Why?
| Anniversaries and Special Events | 1 | 2010 | 14 | 0.410 |
Why?
| Multiple Organ Failure | 1 | 2010 | 44 | 0.400 |
Why?
| Practice Guidelines as Topic | 4 | 2014 | 1088 | 0.400 |
Why?
| Recovery of Function | 1 | 2011 | 264 | 0.390 |
Why?
| Neuromuscular Blocking Agents | 1 | 2009 | 35 | 0.390 |
Why?
| Patient Discharge | 1 | 2011 | 225 | 0.390 |
Why?
| Medical Staff, Hospital | 1 | 2010 | 113 | 0.390 |
Why?
| Hysterectomy | 1 | 2009 | 86 | 0.380 |
Why?
| Adult | 27 | 2021 | 26132 | 0.380 |
Why?
| Personnel Staffing and Scheduling | 1 | 2010 | 89 | 0.380 |
Why?
| Tidal Volume | 1 | 2008 | 52 | 0.380 |
Why?
| Inhalation | 1 | 2008 | 31 | 0.380 |
Why?
| Analgesics | 1 | 2009 | 125 | 0.360 |
Why?
| Extravascular Lung Water | 1 | 2008 | 6 | 0.360 |
Why?
| Physician Executives | 1 | 2008 | 24 | 0.360 |
Why?
| Dermatitis Herpetiformis | 3 | 2006 | 9 | 0.350 |
Why?
| Societies, Medical | 1 | 2012 | 579 | 0.350 |
Why?
| Risk Factors | 9 | 2014 | 5451 | 0.350 |
Why?
| Lymph Node Excision | 1 | 2009 | 210 | 0.350 |
Why?
| Periodicals as Topic | 1 | 2010 | 168 | 0.340 |
Why?
| Patient Admission | 1 | 2008 | 114 | 0.340 |
Why?
| Adrenal Insufficiency | 1 | 2006 | 23 | 0.330 |
Why?
| Muscular Diseases | 1 | 2007 | 73 | 0.330 |
Why?
| Uterine Cervical Neoplasms | 1 | 2009 | 249 | 0.320 |
Why?
| Young Adult | 8 | 2021 | 6007 | 0.320 |
Why?
| Pemphigoid, Benign Mucous Membrane | 2 | 2017 | 5 | 0.320 |
Why?
| E-Selectin | 1 | 2006 | 35 | 0.320 |
Why?
| Interleukin-8 | 1 | 2006 | 86 | 0.320 |
Why?
| Occupational Therapy | 3 | 2010 | 16 | 0.310 |
Why?
| Early Ambulation | 3 | 2010 | 21 | 0.310 |
Why?
| Academic Medical Centers | 2 | 2010 | 395 | 0.310 |
Why?
| Myocardial Ischemia | 1 | 2007 | 173 | 0.290 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2006 | 696 | 0.290 |
Why?
| Brain Diseases | 1 | 2006 | 188 | 0.280 |
Why?
| Heart Arrest | 3 | 2012 | 265 | 0.280 |
Why?
| Drug Therapy, Combination | 3 | 2015 | 994 | 0.260 |
Why?
| Retrospective Studies | 12 | 2020 | 7791 | 0.260 |
Why?
| Endothelial Cells | 1 | 2006 | 404 | 0.250 |
Why?
| Respiratory Insufficiency | 3 | 2010 | 156 | 0.250 |
Why?
| Pemphigoid, Bullous | 2 | 1999 | 12 | 0.240 |
Why?
| Autoantigens | 2 | 2020 | 136 | 0.230 |
Why?
| Coronary Artery Disease | 1 | 2007 | 373 | 0.230 |
Why?
| Bed Rest | 3 | 2010 | 9 | 0.230 |
Why?
| Vital Signs | 2 | 2012 | 38 | 0.230 |
Why?
| Scleroderma, Localized | 1 | 2020 | 9 | 0.220 |
Why?
| Scleroderma, Systemic | 1 | 2020 | 40 | 0.210 |
Why?
| Iron-Binding Proteins | 1 | 2020 | 15 | 0.210 |
Why?
| Propofol | 2 | 2014 | 96 | 0.210 |
Why?
| Elasticity Imaging Techniques | 1 | 2020 | 58 | 0.210 |
Why?
| Treatment Outcome | 8 | 2018 | 7961 | 0.210 |
Why?
| Histocompatibility Antigens Class I | 1 | 2021 | 205 | 0.200 |
Why?
| Survivors | 2 | 2011 | 202 | 0.200 |
Why?
| Graft vs Host Disease | 1 | 2020 | 338 | 0.180 |
Why?
| Sepsis | 2 | 2014 | 303 | 0.180 |
Why?
| Iodide Peroxidase | 1 | 2020 | 187 | 0.180 |
Why?
| Logistic Models | 5 | 2014 | 1166 | 0.180 |
Why?
| Fluorescent Antibody Technique, Direct | 1 | 2017 | 11 | 0.180 |
Why?
| Carcinoma, Basal Cell | 1 | 2018 | 52 | 0.180 |
Why?
| Guideline Adherence | 2 | 2011 | 226 | 0.180 |
Why?
| Conjunctival Diseases | 1 | 2017 | 8 | 0.180 |
Why?
| Spectrum Analysis | 1 | 2018 | 130 | 0.170 |
Why?
| Conjunctiva | 1 | 2017 | 24 | 0.170 |
Why?
| Adjuvants, Immunologic | 1 | 2018 | 166 | 0.170 |
Why?
| Chronic Disease | 1 | 2021 | 977 | 0.170 |
Why?
| Cohort Studies | 4 | 2014 | 2730 | 0.170 |
Why?
| United States | 5 | 2016 | 6394 | 0.160 |
Why?
| Adolescent | 6 | 2021 | 9209 | 0.160 |
Why?
| Dermatomycoses | 1 | 2015 | 13 | 0.160 |
Why?
| Skin Neoplasms | 2 | 2018 | 545 | 0.150 |
Why?
| Costs and Cost Analysis | 1 | 2016 | 153 | 0.150 |
Why?
| Case-Control Studies | 5 | 2018 | 1833 | 0.150 |
Why?
| Hospitalization | 3 | 2016 | 778 | 0.150 |
Why?
| Opportunistic Infections | 1 | 2015 | 68 | 0.150 |
Why?
| Severity of Illness Index | 3 | 2020 | 1784 | 0.150 |
Why?
| Cytokines | 1 | 1999 | 763 | 0.150 |
Why?
| Immobilization | 1 | 2014 | 24 | 0.140 |
Why?
| Wakefulness | 2 | 2012 | 132 | 0.140 |
Why?
| Muscle Fibers, Skeletal | 1 | 2014 | 50 | 0.140 |
Why?
| Health Care Costs | 1 | 2016 | 225 | 0.140 |
Why?
| Fentanyl | 1 | 2014 | 68 | 0.130 |
Why?
| Canada | 1 | 2014 | 208 | 0.130 |
Why?
| Immune System Diseases | 1 | 2014 | 25 | 0.130 |
Why?
| Confidence Intervals | 2 | 2011 | 234 | 0.130 |
Why?
| History, 21st Century | 1 | 2014 | 182 | 0.130 |
Why?
| Dermatology | 3 | 2003 | 34 | 0.130 |
Why?
| Respiratory Function Tests | 1 | 2013 | 148 | 0.130 |
Why?
| Hyperglycemia | 1 | 2014 | 184 | 0.130 |
Why?
| Vasopressins | 1 | 2013 | 51 | 0.130 |
Why?
| Vasoconstrictor Agents | 1 | 2013 | 53 | 0.120 |
Why?
| Bacteremia | 1 | 2014 | 118 | 0.120 |
Why?
| Predictive Value of Tests | 4 | 2018 | 1774 | 0.120 |
Why?
| History, 20th Century | 1 | 2014 | 319 | 0.120 |
Why?
| Remote Consultation | 2 | 2003 | 14 | 0.120 |
Why?
| Norepinephrine | 1 | 2013 | 182 | 0.120 |
Why?
| Aged, 80 and over | 7 | 2017 | 6604 | 0.120 |
Why?
| Prospective Studies | 5 | 2018 | 4121 | 0.120 |
Why?
| Regression Analysis | 1 | 2013 | 628 | 0.120 |
Why?
| Prognosis | 3 | 2014 | 3728 | 0.110 |
Why?
| Withholding Treatment | 1 | 2012 | 115 | 0.110 |
Why?
| Work | 1 | 2011 | 17 | 0.110 |
Why?
| Triage | 1 | 2012 | 103 | 0.110 |
Why?
| Hematologic Neoplasms | 1 | 2014 | 295 | 0.110 |
Why?
| Staphylococcal Infections | 1 | 2014 | 289 | 0.110 |
Why?
| Catheterization, Central Venous | 2 | 2009 | 132 | 0.110 |
Why?
| Carcinoma, Squamous Cell | 1 | 2018 | 1037 | 0.110 |
Why?
| Pneumonia | 1 | 2011 | 157 | 0.110 |
Why?
| After-Hours Care | 1 | 2010 | 8 | 0.110 |
Why?
| Staphylococcus aureus | 1 | 2014 | 293 | 0.110 |
Why?
| Night Care | 1 | 2010 | 11 | 0.110 |
Why?
| Convalescence | 1 | 2010 | 9 | 0.110 |
Why?
| Time Factors | 5 | 2012 | 5514 | 0.100 |
Why?
| Neurologic Examination | 1 | 2010 | 119 | 0.100 |
Why?
| Circadian Rhythm | 1 | 2012 | 310 | 0.100 |
Why?
| Chicago | 2 | 2011 | 1454 | 0.100 |
Why?
| Exercise Therapy | 1 | 2009 | 67 | 0.090 |
Why?
| Ventilators, Mechanical | 1 | 2008 | 32 | 0.090 |
Why?
| Cross-Sectional Studies | 2 | 2012 | 1452 | 0.090 |
Why?
| Neck | 1 | 2009 | 94 | 0.090 |
Why?
| Quality Assurance, Health Care | 1 | 2010 | 229 | 0.090 |
Why?
| Survival Analysis | 2 | 2014 | 1591 | 0.090 |
Why?
| Animals | 3 | 2013 | 27160 | 0.090 |
Why?
| Insulin Resistance | 2 | 2014 | 391 | 0.090 |
Why?
| Sleep | 1 | 2012 | 435 | 0.090 |
Why?
| Pulmonary Edema | 1 | 2008 | 55 | 0.090 |
Why?
| Evidence-Based Medicine | 1 | 2010 | 455 | 0.090 |
Why?
| Natriuretic Peptide, Brain | 1 | 2008 | 70 | 0.090 |
Why?
| Patient-Centered Care | 1 | 2009 | 182 | 0.080 |
Why?
| Lymphatic Diseases | 1 | 2007 | 38 | 0.080 |
Why?
| ROC Curve | 4 | 2012 | 764 | 0.080 |
Why?
| Butyrophenones | 1 | 2006 | 5 | 0.080 |
Why?
| Central Venous Pressure | 1 | 2006 | 27 | 0.080 |
Why?
| Movement | 1 | 2009 | 302 | 0.080 |
Why?
| Thoracotomy | 1 | 2007 | 59 | 0.080 |
Why?
| RNA, Messenger | 2 | 2006 | 2008 | 0.080 |
Why?
| Health Care Surveys | 1 | 2008 | 302 | 0.080 |
Why?
| L-Selectin | 1 | 2006 | 15 | 0.080 |
Why?
| Jugular Veins | 1 | 2006 | 76 | 0.080 |
Why?
| Attitude of Health Personnel | 1 | 2012 | 656 | 0.080 |
Why?
| Gastroenteritis | 1 | 2006 | 24 | 0.080 |
Why?
| Transglutaminases | 1 | 2006 | 39 | 0.080 |
Why?
| Hypercapnia | 1 | 2006 | 50 | 0.080 |
Why?
| Immunoglobulin A | 2 | 2006 | 98 | 0.080 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 75 | 0.080 |
Why?
| Decision Making | 2 | 2012 | 619 | 0.080 |
Why?
| Biopsy, Needle | 1 | 2007 | 268 | 0.080 |
Why?
| Robotics | 1 | 2009 | 254 | 0.080 |
Why?
| Body Weight | 1 | 2008 | 504 | 0.080 |
Why?
| Coma | 1 | 2006 | 40 | 0.080 |
Why?
| Interleukin-1 | 1 | 2005 | 74 | 0.080 |
Why?
| Proportional Hazards Models | 3 | 2014 | 873 | 0.080 |
Why?
| Endosonography | 1 | 2007 | 133 | 0.080 |
Why?
| Physical Examination | 1 | 2006 | 153 | 0.080 |
Why?
| GTP-Binding Proteins | 1 | 2006 | 163 | 0.080 |
Why?
| Physicians | 1 | 2012 | 610 | 0.070 |
Why?
| Lung | 1 | 2011 | 1078 | 0.070 |
Why?
| Interleukin-6 | 1 | 2005 | 238 | 0.070 |
Why?
| Monocytes | 1 | 2005 | 230 | 0.070 |
Why?
| Risk Assessment | 1 | 2012 | 2294 | 0.070 |
Why?
| Pain | 1 | 2006 | 364 | 0.070 |
Why?
| Quality of Life | 1 | 2011 | 1379 | 0.060 |
Why?
| Dapsone | 1 | 1982 | 10 | 0.060 |
Why?
| Affect | 1 | 2005 | 393 | 0.060 |
Why?
| Lymph Nodes | 1 | 2007 | 535 | 0.060 |
Why?
| Skin Diseases, Vesiculobullous | 1 | 1982 | 18 | 0.060 |
Why?
| Disease Models, Animal | 1 | 2010 | 2317 | 0.060 |
Why?
| Laparoscopy | 1 | 2009 | 712 | 0.060 |
Why?
| Prevalence | 1 | 2007 | 1271 | 0.060 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2006 | 868 | 0.060 |
Why?
| Stress, Psychological | 1 | 2005 | 309 | 0.060 |
Why?
| Medical Records Systems, Computerized | 1 | 2002 | 42 | 0.060 |
Why?
| Single-Blind Method | 2 | 2014 | 160 | 0.060 |
Why?
| Follow-Up Studies | 3 | 2017 | 3883 | 0.060 |
Why?
| Lupus Erythematosus, Systemic | 1 | 1982 | 190 | 0.050 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 326 | 0.050 |
Why?
| Interleukin-5 | 1 | 1999 | 36 | 0.050 |
Why?
| Child | 3 | 2006 | 6845 | 0.050 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 1999 | 58 | 0.050 |
Why?
| Interleukin-13 | 1 | 1999 | 31 | 0.050 |
Why?
| Interleukin-4 | 1 | 1999 | 139 | 0.050 |
Why?
| Referral and Consultation | 1 | 2002 | 326 | 0.050 |
Why?
| In Situ Hybridization | 1 | 1999 | 324 | 0.050 |
Why?
| Electrocardiography | 2 | 2012 | 595 | 0.050 |
Why?
| Interleukin-2 | 1 | 1999 | 287 | 0.050 |
Why?
| Eosinophils | 1 | 1999 | 193 | 0.050 |
Why?
| Feasibility Studies | 1 | 2020 | 760 | 0.040 |
Why?
| Cell Adhesion | 1 | 1999 | 429 | 0.040 |
Why?
| Keratosis | 1 | 1997 | 22 | 0.040 |
Why?
| Sensitivity and Specificity | 3 | 2012 | 2082 | 0.040 |
Why?
| Basement Membrane | 1 | 2017 | 61 | 0.040 |
Why?
| Interferon-gamma | 1 | 1999 | 463 | 0.040 |
Why?
| Non-Fibrillar Collagens | 1 | 1996 | 3 | 0.040 |
Why?
| Chi-Square Distribution | 2 | 2011 | 379 | 0.040 |
Why?
| Remission Induction | 1 | 2018 | 716 | 0.040 |
Why?
| Biopsy | 2 | 2017 | 1189 | 0.040 |
Why?
| Fungemia | 1 | 2015 | 24 | 0.040 |
Why?
| Glucocorticoids | 1 | 2018 | 362 | 0.040 |
Why?
| Cytoskeletal Proteins | 1 | 1996 | 231 | 0.040 |
Why?
| Pilot Projects | 1 | 2018 | 838 | 0.040 |
Why?
| Insulin | 2 | 2014 | 1172 | 0.040 |
Why?
| Collagen | 1 | 1996 | 277 | 0.040 |
Why?
| Muscle Strength | 1 | 2014 | 35 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2007 | 2131 | 0.030 |
Why?
| Immunohistochemistry | 1 | 1999 | 1826 | 0.030 |
Why?
| Diagnostic Tests, Routine | 1 | 2014 | 65 | 0.030 |
Why?
| Hospitals, Teaching | 1 | 2014 | 127 | 0.030 |
Why?
| Cells, Cultured | 1 | 1999 | 2974 | 0.030 |
Why?
| Nerve Tissue Proteins | 1 | 1996 | 530 | 0.030 |
Why?
| Lighting | 1 | 2012 | 30 | 0.030 |
Why?
| North Carolina | 2 | 2003 | 49 | 0.030 |
Why?
| Urban Population | 1 | 2014 | 228 | 0.030 |
Why?
| Carrier Proteins | 1 | 1996 | 689 | 0.030 |
Why?
| Melatonin | 1 | 2012 | 43 | 0.030 |
Why?
| Resuscitation | 1 | 2013 | 95 | 0.030 |
Why?
| Sleep, REM | 1 | 2012 | 62 | 0.030 |
Why?
| Professional-Family Relations | 1 | 2012 | 51 | 0.030 |
Why?
| Hospital Rapid Response Team | 1 | 2012 | 30 | 0.030 |
Why?
| Polysomnography | 1 | 2012 | 188 | 0.030 |
Why?
| American Heart Association | 1 | 2011 | 88 | 0.030 |
Why?
| Exercise | 1 | 2014 | 283 | 0.030 |
Why?
| Early Diagnosis | 1 | 2011 | 130 | 0.030 |
Why?
| Hospitals, University | 1 | 2011 | 205 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2017 | 2683 | 0.030 |
Why?
| Physician's Role | 1 | 2012 | 187 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2014 | 2104 | 0.020 |
Why?
| Blood Glucose | 1 | 2014 | 904 | 0.020 |
Why?
| Iowa | 1 | 2009 | 36 | 0.020 |
Why?
| Mobility Limitation | 1 | 2009 | 16 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 1014 | 0.020 |
Why?
| Heart Rate | 1 | 2011 | 564 | 0.020 |
Why?
| Activities of Daily Living | 1 | 2009 | 190 | 0.020 |
Why?
| Diagnosis, Differential | 2 | 2007 | 1611 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2011 | 991 | 0.020 |
Why?
| Survival Rate | 1 | 2011 | 1924 | 0.020 |
Why?
| Medical Staff | 1 | 2006 | 12 | 0.020 |
Why?
| Age Factors | 1 | 2011 | 1923 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2009 | 901 | 0.020 |
Why?
| Ultrasonography | 1 | 2009 | 698 | 0.020 |
Why?
| Primary Health Care | 2 | 2002 | 298 | 0.020 |
Why?
| Cognition | 1 | 2010 | 504 | 0.020 |
Why?
| Blood Pressure Determination | 1 | 2006 | 97 | 0.020 |
Why?
| Blood Pressure | 1 | 2011 | 1207 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2006 | 448 | 0.020 |
Why?
| Anger | 1 | 2005 | 69 | 0.020 |
Why?
| Arousal | 1 | 2005 | 169 | 0.020 |
Why?
| Lymphatic Metastasis | 1 | 2007 | 509 | 0.020 |
Why?
| Lipopolysaccharides | 1 | 2005 | 278 | 0.020 |
Why?
| Reference Values | 1 | 2005 | 704 | 0.020 |
Why?
| Homeostasis | 1 | 2005 | 400 | 0.020 |
Why?
| HLA Antigens | 2 | 1981 | 228 | 0.020 |
Why?
| Hospitals, Veterans | 1 | 2002 | 19 | 0.010 |
Why?
| Time and Motion Studies | 1 | 2002 | 22 | 0.010 |
Why?
| Outpatient Clinics, Hospital | 1 | 2002 | 26 | 0.010 |
Why?
| Neoplasm Staging | 1 | 2007 | 1933 | 0.010 |
Why?
| Cost-Benefit Analysis | 1 | 2003 | 411 | 0.010 |
Why?
| Adrenal Cortex Hormones | 1 | 1982 | 266 | 0.010 |
Why?
| Histocompatibility Antigens Class II | 1 | 1981 | 174 | 0.010 |
Why?
| Models, Biological | 1 | 2005 | 1799 | 0.010 |
Why?
| Epitope Mapping | 1 | 1996 | 20 | 0.010 |
Why?
| Japan | 1 | 1996 | 292 | 0.010 |
Why?
| Immunoblotting | 1 | 1996 | 279 | 0.010 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 411 | 0.010 |
Why?
| Observer Variation | 1 | 1997 | 622 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 1996 | 572 | 0.010 |
Why?
| Clinical Competence | 1 | 1997 | 710 | 0.010 |
Why?
| Antigen-Antibody Complex | 2 | 1981 | 97 | 0.010 |
Why?
| Complement System Proteins | 1 | 1980 | 91 | 0.000 |
Why?
| Celiac Disease | 1 | 1980 | 196 | 0.000 |
Why?
| T-Lymphocytes | 1 | 1981 | 1304 | 0.000 |
Why?
|
|
Hall's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Physical Neighbors  People whose addresses are nearby this person. _
|